Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Exelixis, Inc.'s Thyroid Cancer Drug Gets FDA Priority Review-Reuters
Reuters reported that U.S. health regulators granted a priority review for Exelixis, Inc. experimental drug to treat a rare form of thyroid cancer. Exelixis said the U.S. Food and Drug Administration set a review date of November 29 for the drug, cabozantinib, designed to treat medullary thyroid cancer. Medullary thyroid cancer, which starts in cells that release a hormone called calcitonin, accounts for about 4% of thyroid cancers. The FDA grants priority review to expedite the review of drugs to treat serious diseases and fill unmet medical needs.
Latest Developments for Exelixis Inc
- Exelixis Inc Reaffirms FY 2012 Revenue Guidance
- Exelixis Inc Announces Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer
- Exelixis Inc Announces Preliminary Phase 1 Data for Cabozantinib in Japanese Patients
- Exelixis, Inc. Announces Pricing Of Concurrent Offerings Of 30 Million Shares Of Common Stock And $250 Million Principal Amount Of Convertible Senior Subordinated Notes
Latest Key Developments in Biotechnology
- Omeros Corp Announces Clearence Of New Drug Application By FDA For OMS824 In Huntington's Disease
- Miraca Holdings Inc Appoints Corporate Auditor
- Bioxyne Ltd Announces Termination Of Proposed Acquisition Of Vitality Devices Pty Ltd
- Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Share this
- Link this
- Digg this
Follow Reuters